BPIQ Pro/Elite/Apex Investor Posts

BPIQ’s June 2026 Hedge Fund Stock Picks highlight three biopharma names with different catalyst profiles. This Pro version features the full CLDX pick, including its later-stage immunology setup, pivotal data ahead, and downloadable PDF report.

ASCO 2026 was not only about individual readouts. Across five days, the meeting showed where oncology innovation is moving next: more targeted, more biomarker-driven, and increasingly built around complex therapeutic platforms. From BPIQ’s lens, several technology themes stood out. ADCs Stayed at the Center of Oncology Antibody-drug conjugates remained one of the most active modalities across the meeting. Nectin-4 was especially visible, with Corbus, Eli Lilly, and Bicycle Th

ASCO 2026 delivered important updates across hematologic malignancies, lung cancer, breast cancer, gastrointestinal cancers, melanoma, and several rare and difficult-to-treat tumors. Across the meeting, ADCs, bispecific antibodies, cell therapies, radioligand approaches, and increasingly precise biomarker-driven strategies remained at the center of oncology innovation. One presentation stood above the rest. During the Day 3 Plenary Session, Revolution Medicines presented what

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Background After extensive back-testing to find to identify the best strategies for using consensus holdings of top institutional investors to consistently beat the biotech benchmarks, we launched our first consensus-based portfolio (Top 20s) on 4/1/2023. By 9/30/2023, we applied the hedge fund favo

Day 2 of ASCO 2026 shifted the spotlight from ADC-heavy discussions toward cell therapy, precision oncology, and several important late-stage studies. While major pharmaceutical companies continued to present updates from established programs, some of the most interesting stories came from companies advancing TCR-T therapies, next-generation targeted treatments, and novel immunotherapy approaches. Here are five tickers that stood out: IMTX: TCR-T Therapy Continues Its Push in

ASCO is one of the most important events on the biotech calendar, but not every presentation captures investors' attention equally. Day 1 featured dozens of clinical updates across oncology, yet a handful of companies stood out because of the technologies they are advancing, the markets they are targeting, and the potential impact on future valuations. Here are five tickers that mattered on Day 1 of ASCO 2026. NUVL: Building a Potential Next-Generation ALK Franchise Nuvalent

ASCO is one of the most important weeks of the year for biotech investors. Clinical updates presented during the meeting can rapidly reshape company narratives, regulatory expectations, partnership interest, and valuation outlooks, especially for small and mid-cap oncology companies. Using BPIQ MCP, we screened for companies where ASCO 2026 presentations could represent meaningful inflection points. The final list includes pivotal Phase 3 datasets, late-stage regulatory setup

Summary

Following our latest portfolio update, a few companies appeared across multiple BPIQ portfolios. Since Top 10A, Top 10B, and Top 15 use different portfolio construction approaches, many stocks appear in only one portfolio. When a company appears across multiple portfolios, it suggests that it ranks highly across multiple versions of our hedge fund consensus framework. Examples from the latest update: DYN → included in Top 10A, Top 10B, and Top 15 ORIC → included in Top 10A an

With the latest hedge fund filings incorporated into our portfolio targets, many subscribers ask a similar question: Why does BPIQ maintain multiple portfolio strategies instead of a single portfolio? The answer is simple. While all of our core portfolios are built from the same foundation, top holdings and consensus positions of biotech-focused hedge funds, portfolio construction matters. As discussed in our recent blog, consensus is the signal, structure is the edge. Years

The new holding targets for our three quarterly-adjusted BPIQ model portfolios, Top10A, Top15, and Top10B, have now been updated. Elite and APEX subscribers can view the latest portfolio targets here: 👉 https://app.bpiq.com/model-portfolios/hf-targets You can also track quarter-over-quarter changes, including stocks that were added or removed, along with their percentage change based on the latest update as of 5/16/26: 👉 https://app.bpiq.com/model-portfolios/hf-targets-chan

Biotech investing is not limited by access to information.It is limited by the ability to make consistently better decisions in a highly uncertain environment. Even deep diligence and strong science often fail to translate into consistent outcomes. This led us to shift away from picking individual winners and toward understanding how experienced biotech investors allocate capital. One pattern stood out: Companies held across multiple top biotech-focused hedge funds tend to ou

Dyne Therapeutics is our May 2026 Hedge Fund Favorite Spotlight, with strong institutional interest, a differentiated neuromuscular pipeline, and upcoming catalyst potential. DYN was held by 13 of 34 biotech-focused hedge funds in Q4 2025, placing it well above the typical median holding level across the group. The company’s lead program, DYNE-251, is being advanced for Duchenne muscular dystrophy and is expected to reach BLA submission milestone in Q2 2026. From an investor

At AACR 2026, several first-time disclosed oncology programs highlighted how public biotech and pharma companies are positioning for the next wave of innovation. From an investor perspective, the key question remains: Does this asset improve the company’s position in a real, competitive market? Below is a focused look at newly disclosed assets from public companies, through four lenses: disease target, competition, technology, and potential market impact. 🟢 AstraZeneca: Prec

Biotech investing is not limited by access to information. It is limited by the ability to pick winning stocks and winning portfolio strategies. Even with strong science and data, consistent outperformance is difficult to achieve for any individual investor or investment group. With an investing background in biotech dating back to the late 1990s, we have seen that deep diligence by even a very experienced biotech pro on individual companies still often leads to disappointing

Q4 13F filings are now available.

Summary

The JP Morgan Healthcare Conference generates thousands of data points every year, including company presentations, slide decks, pipeline updates, guidance revisions, and strategic commentary.

After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why?

BPIQ has launched a new feature called High Management Interest , available exclusively to BPIQ APEX subscribers. High Management Interest is designed to help investors identify Big Movers and Suspected Movers where company management has publicly signaled a high level of strategic focus or confidence around an upcoming catalyst. What Is High Management Interest? High Management Interest highlights companies with upcoming Big Mover or Suspected Mover catalysts where manag